An Open-label, Micro-dosing Study to Evaluate Safety, Biodistribution, Dosimetry and Preliminary Efficacy of Two Single 68Ga-OPS202 Doses for the Diagnostic Imaging of Somatostatin Receptor-positive Gastro-entero-pancreatic Neuroendocrine Tumors (GEP NET) Using Positron-emission Tomography / Computed Tomography (PET/CT)

Trial Profile

An Open-label, Micro-dosing Study to Evaluate Safety, Biodistribution, Dosimetry and Preliminary Efficacy of Two Single 68Ga-OPS202 Doses for the Diagnostic Imaging of Somatostatin Receptor-positive Gastro-entero-pancreatic Neuroendocrine Tumors (GEP NET) Using Positron-emission Tomography / Computed Tomography (PET/CT)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Mar 2016

At a glance

  • Drugs Gallium 68 satoreotide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Adverse reactions
  • Sponsors OctreoPharm Sciences
  • Most Recent Events

    • 21 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 04 May 2015 Planned End Date changed from 1 Apr 2015 to 1 Jun 2015, as reported by ClinicalTrials.gov.
    • 04 May 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Jun 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top